Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Where have Eurofins moved the Camberley production to, because if I am correct the property on Watchpoint road is back on the market for lease as of 23/01/23
https://property link.estatesgazette.com/property-details/6879781-unit-1a-watchmoor-point-watchmoor-road
Laughoutloud, the government website shows availability for commercial court cases of more than 14 day's from February 2024. We are due a general election in 2024 and looking back May is a favoured month . If a May election date was chosen would the government want an earlier court case while they are on the campaign trail?
Hi Kaeren/ Larry, I took a look at the accounts for the full year 2021 and H1 2022. From what I can see the money for the second and third payments of the LTIP has been held in foreign currencies under the section for financial income and expenses. In the full year accounts for 2021 a financial foreign exchange loss of just over £2million was showing for this money . Could this be one of the reasons why they initially withheld the 2021 payment . Moving on to the H1 accounts for 2022 there is a substantial foreign exchange gain showing for the 6 months and if you look under other liabilities it shows that the withheld payment for 2021 has now been paid. Comments at the end of the trade and liabilities section state -
Other liabilities have fallen as a result of payments being made in relation to the 2017/2020 LTIP scheme, leaving the final tranche which is forecast to be paid by the end of 2022.
Just to add to my comment last night I can't see that DA would have been happy agreeing to such large outflows of cash when so little money was coming in .
P101, you've already told this board you only read the first two lines of an rns ,so wouldn't know that the accounts stated that the final payment was to be made in 2022( November 1st being the yearly anniversary date as per the original agreement).
I don't know if anyone has already seen this notice that was published on Bidstats last week. A new four year framework, valued up to £20 billion is being set up to provide the NHS with a full range of testing services. This is made up of 10 different lots, one of which is for point of care testing and the the final two are for innovation . Novacyt now have a range of clinical tests, hopefully they will apply to be on the framework and compete for business.
https://bidstats.uk/tenders/2023/W03/790888827
Hi Wilson, the second half of this article contains some info on the MHRA proposing an alternative route to market for tests .From what I can find out a further announcement is due.
https://www.penningtonlaw.com/news-publications/latest-news/2022/same-old-same-old-but-different-the-proposed-uk-framework-for-medical-device-regulations
Try a different link
https://www.bsigroup.com/en-GB/medical-devices/technologies/ivd/
Harv, is an ivd not classed as a medical device?
https://ec.europa.eu/commission/presscorner/detail/en/quanda_21_5210
This link gives some info on what is involved in taking a medical device from the proof of concept stage to actual launch. From what Novacyt have told us they are developing multiplex tests using the Promate chemistry for respiratory and gastric infections. Hopefully the update at the end of the month will provide some info on how these are progressing and maybe the pipeline page on their website will be brought in line with where the development and regulatory approval is at .
https://www.scilife.io/blog/5-medical-device-development-phases
For those that haven't seen this article before it gives a short insight into JM.
https://www.nurole.com/news-and-guides/james-mccarthy-cfo-goldman-sachs-and-koch-industries-backed-flint-group
P101, where are Biosynex getting these shares from that they are selling? You told this board last summer that they had sold out. Did they buy back in again or was that just another off the top of your head statements aimed to mislead shareholders.
Hopefully there will be an update later this month about how the validation work on all those Clonit assays has been going with the q16 and q32 devices. When the contract was announced at the end of September Novacyt had already validated the STI assays, so significant progress should have been made by now on the respiratory and gastric assays.
It looks like the two gastric test panels that were mentioned in the shareholder presentation could come from the Experteam product list.
https://www.linkedin.com/company/clonit-srl/